Cargando…

Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study

PURPOSE: To compare the efficacy of an antibiotic protocol guided by serum procalcitonin (PCT) with that of standard antibiotic therapy in severe acute exacerbations of COPD (AECOPDs) admitted to the intensive care unit (ICU). METHODS: We conducted a multicenter, randomized trial in France. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Daubin, Cédric, Valette, Xavier, Thiollière, Fabrice, Mira, Jean-Paul, Hazera, Pascal, Annane, Djillali, Labbe, Vincent, Floccard, Bernard, Fournel, François, Terzi, Nicolas, Du Cheyron, Damien, Parienti, Jean-Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924665/
https://www.ncbi.nlm.nih.gov/pubmed/29663044
http://dx.doi.org/10.1007/s00134-018-5141-9
_version_ 1783318579506053120
author Daubin, Cédric
Valette, Xavier
Thiollière, Fabrice
Mira, Jean-Paul
Hazera, Pascal
Annane, Djillali
Labbe, Vincent
Floccard, Bernard
Fournel, François
Terzi, Nicolas
Du Cheyron, Damien
Parienti, Jean-Jacques
author_facet Daubin, Cédric
Valette, Xavier
Thiollière, Fabrice
Mira, Jean-Paul
Hazera, Pascal
Annane, Djillali
Labbe, Vincent
Floccard, Bernard
Fournel, François
Terzi, Nicolas
Du Cheyron, Damien
Parienti, Jean-Jacques
author_sort Daubin, Cédric
collection PubMed
description PURPOSE: To compare the efficacy of an antibiotic protocol guided by serum procalcitonin (PCT) with that of standard antibiotic therapy in severe acute exacerbations of COPD (AECOPDs) admitted to the intensive care unit (ICU). METHODS: We conducted a multicenter, randomized trial in France. Patients experiencing severe AECOPDs were assigned to groups whose antibiotic therapy was guided by (1) a 5-day PCT algorithm with predefined cutoff values for the initiation or stoppage of antibiotics (PCT group) or (2) standard guidelines (control group). The primary endpoint was 3-month mortality. The predefined noninferiority margin was 12%. RESULTS: A total of 302 patients were randomized into the PCT (n = 151) and control (n = 151) groups. Thirty patients (20%) in the PCT group and 21 patients (14%) in the control group died within 3 months of admission (adjusted difference, 6.6%; 90% CI − 0.3 to 13.5%). Among patients without antibiotic therapy at baseline (n = 119), the use of PCT significantly increased 3-month mortality [19/61 (31%) vs. 7/58 (12%), p = 0.015]. The in-ICU and in-hospital antibiotic exposure durations, were similar between the PCT and control group (5.2 ± 6.5 days in the PCT group vs. 5.4 ± 4.4 days in the control group, p = 0.85 and 7.9 ± 8 days in the PCT group vs. 7.7 ± 5.7 days in the control group, p = 0.75, respectively). CONCLUSION: The PCT group failed to demonstrate non-inferiority with respect to 3-month mortality and failed to reduce in-ICU and in-hospital antibiotic exposure in AECOPDs admitted to the ICU. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00134-018-5141-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5924665
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-59246652018-05-01 Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study Daubin, Cédric Valette, Xavier Thiollière, Fabrice Mira, Jean-Paul Hazera, Pascal Annane, Djillali Labbe, Vincent Floccard, Bernard Fournel, François Terzi, Nicolas Du Cheyron, Damien Parienti, Jean-Jacques Intensive Care Med Seven-Day Profile Publication PURPOSE: To compare the efficacy of an antibiotic protocol guided by serum procalcitonin (PCT) with that of standard antibiotic therapy in severe acute exacerbations of COPD (AECOPDs) admitted to the intensive care unit (ICU). METHODS: We conducted a multicenter, randomized trial in France. Patients experiencing severe AECOPDs were assigned to groups whose antibiotic therapy was guided by (1) a 5-day PCT algorithm with predefined cutoff values for the initiation or stoppage of antibiotics (PCT group) or (2) standard guidelines (control group). The primary endpoint was 3-month mortality. The predefined noninferiority margin was 12%. RESULTS: A total of 302 patients were randomized into the PCT (n = 151) and control (n = 151) groups. Thirty patients (20%) in the PCT group and 21 patients (14%) in the control group died within 3 months of admission (adjusted difference, 6.6%; 90% CI − 0.3 to 13.5%). Among patients without antibiotic therapy at baseline (n = 119), the use of PCT significantly increased 3-month mortality [19/61 (31%) vs. 7/58 (12%), p = 0.015]. The in-ICU and in-hospital antibiotic exposure durations, were similar between the PCT and control group (5.2 ± 6.5 days in the PCT group vs. 5.4 ± 4.4 days in the control group, p = 0.85 and 7.9 ± 8 days in the PCT group vs. 7.7 ± 5.7 days in the control group, p = 0.75, respectively). CONCLUSION: The PCT group failed to demonstrate non-inferiority with respect to 3-month mortality and failed to reduce in-ICU and in-hospital antibiotic exposure in AECOPDs admitted to the ICU. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00134-018-5141-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-04-16 2018 /pmc/articles/PMC5924665/ /pubmed/29663044 http://dx.doi.org/10.1007/s00134-018-5141-9 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Seven-Day Profile Publication
Daubin, Cédric
Valette, Xavier
Thiollière, Fabrice
Mira, Jean-Paul
Hazera, Pascal
Annane, Djillali
Labbe, Vincent
Floccard, Bernard
Fournel, François
Terzi, Nicolas
Du Cheyron, Damien
Parienti, Jean-Jacques
Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study
title Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study
title_full Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study
title_fullStr Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study
title_full_unstemmed Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study
title_short Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study
title_sort procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of copd admitted to the icu: a randomized multicenter study
topic Seven-Day Profile Publication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924665/
https://www.ncbi.nlm.nih.gov/pubmed/29663044
http://dx.doi.org/10.1007/s00134-018-5141-9
work_keys_str_mv AT daubincedric procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy
AT valettexavier procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy
AT thiollierefabrice procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy
AT mirajeanpaul procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy
AT hazerapascal procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy
AT annanedjillali procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy
AT labbevincent procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy
AT floccardbernard procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy
AT fournelfrancois procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy
AT terzinicolas procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy
AT ducheyrondamien procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy
AT parientijeanjacques procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy
AT procalcitoninalgorithmtoguideinitialantibiotictherapyinacuteexacerbationsofcopdadmittedtotheicuarandomizedmulticenterstudy